Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

445
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
445
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

352
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
352
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

618
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
618
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

606
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
606

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Concizumab in patients with hemophilia A or B without inhibitors: 56-week cut-off results of the phase 3 explorer8 study.

Blood advances·2026
Same author

Epidemiology, comorbidity patterns and outcomes of maternal sepsis-related coded discharges in Ireland 2020-2025.

European journal of obstetrics, gynecology, and reproductive biology·2026
Same author

Epidemiology and outcomes of adult (non-maternity) community-onset sepsis in Ireland: a secondary analysis of acute hospital administrative data 2020-2024.

Irish journal of medical science·2026
Same author

The diagnostic performance of the YEARS and Pulmonary Embolism Graduated D-dimer algorithms in patients with prior venous thrombosis suspected of pulmonary embolism.

Research and practice in thrombosis and haemostasis·2026
Same author

Proteomic biomarkers differentiate bacterial infections in febrile infants: A multicentre prospective study.

The Journal of infection·2026
Same author

Biomarkers for acute mild brain injury (BAMBI): optimising GFAP/UCH-L1 thresholds to support CT stewardship in a NICE-guided mild-traumatic-brain-injury cohort.

British journal of neurosurgery·2026

相关实验视频

Updated: Mar 13, 2026

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
06:04

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation

Published on: August 8, 2025

675

在急性静脉血栓栓塞症中,阿皮克萨班与里瓦罗克萨班的出血风险

Lana A Castellucci1, Vivien M Chen2,3,4, Michael J Kovacs5

  • 1Department of Medicine, Ottawa Hospital Research Institute at the University of Ottawa, Ottawa.

The New England journal of medicine
|March 11, 2026
PubMed
概括
此摘要是机器生成的。

与里瓦洛克萨班相比,阿皮克萨班在急性静脉血栓塞栓症患者中显著降低了出血风险. 这项为期3个月的试验发现阿皮克萨班是一种更安全的口服抗凝剂选择,降低了临床相关的出血事件.

更多相关视频

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K

相关实验视频

Last Updated: Mar 13, 2026

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
06:04

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation

Published on: August 8, 2025

675
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K

科学领域:

  • 心脏病学 心脏病学
  • 药理学 药理学是指药理学的学科.
  • 临床试验 临床试验

背景情况:

  • 阿皮克萨班和里瓦罗克萨班是治疗急性静脉血栓栓塞 (VTE) 的领先的口服抗凝剂.
  • 在静脉瘤患者中比较阿皮克萨班和里瓦罗克萨班之间的出血风险的临床数据仍然有限.
  • 了解不同出血形状对于优化静脉瘤治疗策略至关重要.

研究的目的:

  • 直接比较患有急性静脉动脉瘤的患者中阿皮克萨班和里瓦罗克萨班之间临床相关出血的发生率.
  • 评估二次结果,包括所有原因的死亡率,在接受抗凝剂治疗的患者中.

主要方法:

  • 一个国际,前性,随机化,开放标签,盲目的终点试验,涉及2760名急性肺栓塞或深静脉血栓塞的患者.
  • 患者接受阿皮克萨班 (10毫克每天两次7天,然后每天两次5毫克) 或里瓦罗克萨班 (15毫克每天两次21天,然后每天20毫克) 3个月.
  • 主要终点是主要或临床相关的非主要出血的组合,使用国际血栓学会和血液静止学会的标准进行评估.

主要成果:

  • 主要结局事件发生在3.3%的阿皮克萨班组和7.1%的里瓦罗克萨班组 (相对风险:0.46;95% CI,0.33-0.65;P<0.001).
  • 在两组中,全因死亡率都很低 (阿皮克萨班为0.1%,里瓦罗克萨班为0.3%).
  • 与出血或血栓形成无关的严重不良事件在两组之间是可比的.

结论:

  • 与里瓦洛克萨班相比,阿皮克萨班在治疗急性静脉血栓栓塞症的患者中显示出临床相关出血的风险明显较低,持续3个月.
  • 这些发现表明,阿皮克萨班可能在这个患者群体中提供更高的安全性概况,以预防出血并发症.
  • 进一步的研究可能会探索长期结果和特定的患者子组.